Welcome to our dedicated page for Caris Life Sciences news (Ticker: CAI), a resource for investors and traders seeking the latest updates and insights on Caris Life Sciences stock.
Caris Life Sciences, Inc. develops and commercializes AI-enabled precision medicine solutions built around comprehensive molecular profiling, next-generation sequencing and machine learning. The company’s diagnostics and data platform use Whole Genome, Whole Exome and Whole Transcriptome Sequencing, a multimodal clinico-genomic database and high-performance computing to support early detection, diagnosis, monitoring, therapy selection and drug development.
Company announcements commonly address molecular profiling services, clinical therapy selection volume, product launches and regulatory or reimbursement actions for tests such as Caris Assure, Caris MI Clarity and Caris ChromoSeq. Other recurring developments include peer-reviewed validation of Caris AI Insights, Caris Precision Oncology Alliance collaborations, conference presentations and quarterly financial results.
Caris Life Sciences (NASDAQ: CAI) announced on April 17, 2026 that the UCSF Helen Diller Family Comprehensive Cancer Center joined the Caris Precision Oncology Alliance (POA). The membership expands collaborative, biomarker-driven research using Caris' AI-driven multimodal database and comprehensive molecular profiling to support personalized cancer care.
Caris Life Sciences (NASDAQ: CAI) announced expansion of its Right-In-Time (RIT) clinical trial solution to bring biomarker-driven trials to community oncology sites nationwide.
The program spans >600 locations, 2,200 investigators and identified >71,000 patients for possible trial participation, using comprehensive WES/WTS/IHC profiling and a trial-matching workflow that can enroll patients in ~2 weeks (as few as 5 days).
Caris Life Sciences (NASDAQ: CAI) launched a multimodal AI-driven molecular signature to guide first-line treatment selection for a subset of PD-L1 ≥50% non-small cell lung cancer (NSCLC) patients.
The signature uses Whole Exome Sequencing, Whole Transcriptome Sequencing and clinical data via the proprietary CodeAI platform to predict which patients benefit from adding chemotherapy versus those harmed by it. Caris notes the insight is proprietary and available to Caris customers; the company previously received FDA approval in November 2024 for its WES/WTS tissue assay MI Cancer Seek.
Caris Life Sciences (NASDAQ: CAI) launched Caris ChromoSeq on April 2, 2026: a combined Whole Genome Sequencing (WGS) and Whole Transcriptome (WTS) assay for myeloid malignancies.
The test delivers ~250x genome read depth, 40 million transcriptome reads, supports bone marrow or peripheral blood samples, and has an expected seven-day turnaround.
Caris Life Sciences (NASDAQ: CAI) finalized Achieve 1 results for Caris Detect, a multi-cancer early detection test using Whole Genome Sequencing. The study enrolled 3,014 evaluable subjects and reported overall Stage I–II sensitivity ~60.3% and high specificities (asymptomatic 99.2%, benign/high-risk 96.0%). Stage-specific sensitivity ranged from 56.8% (Stage I) to 98.6% (Stage IV).
The company emphasized WGS superiority over methylation-only approaches and plans to add additional pillars, including Whole Transcriptome Sequencing, to improve performance.
Caris Life Sciences (NASDAQ: CAI) added two proprietary Caris AI Insights signatures predicting brain metastases risk in breast cancer and non-small cell lung cancer (NSCLC), bringing its total to seven.
The signatures were trained on 12,994 NSCLC and 3,371 breast cases and use WES/WTS data; MI Cancer Seek orders include the report at no extra cost. Caris reports its multimodal dataset exceeds 500,000 patients tested and notes an ongoing study with the Caris Precision Oncology Alliance to highlight the risk‑prediction approach.
Caris Life Sciences (NASDAQ: CAI) will present six oncology studies at the AACR Annual Meeting, April 17-22, 2026, in San Diego. The posters use Caris' multimodal database (WES, WTS, IHC, real-world clinical data) across breast, prostate, lung and colorectal cancers.
Research highlights will be onsite at booth #1423; full abstracts follow the presentations on the company website.
Caris Life Sciences (NASDAQ: CAI) emphasized the importance of DPYD testing for colorectal cancer patients during Colorectal Cancer Awareness Month on March 24, 2026. The company noted the FDA updated safety labeling for capecitabine and 5-FU and incorporated DPYD reporting into its blood-based Caris Assure Whole Exome and Whole Transcriptome Sequencing assay.
This integration enables clinicians to detect inherited DPYD variants from a single blood draw, aiming to inform fluoropyrimidine therapy decisions and reduce risk of severe toxicity before treatment begins.
Caris Life Sciences (NASDAQ: CAI) published a JAMA Network Open study (March 20, 2026) showing its GPSai algorithm reclassified cancer diagnoses among lung squamous cell carcinoma submissions. Of 3,958 cases, GPSai identified 123 as metastases from other primaries; 88 patients (71.5%) had guideline-preferred first-line therapy changes. Caris reports GPSai has overturned 3,857 diagnoses since January 2024. The GPSai capability is included in MI Cancer Seek and MI Tumor Seek; MI Cancer Seek received FDA approval November 2024.
Caris Life Sciences (NASDAQ: CAI) introduced a new platinum resistance AI signature to its Caris AI Insights portfolio on March 16, 2026. The model predicts early platinum resistance in high-grade serous ovarian cancer (HGSOC) using Whole Exome and Whole Transcriptome sequencing plus clinical data, providing a risk score, platinum sensitive/platinum resistant prediction and supporting Kaplan-Meier curves. The insight is available now by request through the Caris Molecular Tumor Board Report when ordering the tissue-based test MI Cancer Seek. Caris previously received FDA approval for MI Cancer Seek in November 2024.